RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Acquisition of Vimentin by trogocytosis inhibits the NK cell-mediated immune response against circulating tumour cells (CTCs).
Acquisition of Vimentin by trogocytosis inhibits the NK cell-mediated immune response against circulating tumour cells (CTCs).
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
自然杀伤(NK)细胞常呈现耗竭状态,这促进了循环肿瘤细胞(CTC)的免疫逃逸。然而,NK细胞功能障碍的潜在机制仍不明确。
在本研究中,我们发现了一种新的免疫逃逸机制,即肿瘤细胞通过NKp46依赖性胞吐作用将Vimentin递送至NK细胞,从而损害NK细胞的细胞毒性。
我们观察到,在口腔癌患者CTC分离出的NK细胞中有非内源性蛋白的表达,而在未检出CTC的患者中则没有。高通量蛋白质组学分析、流式细胞术和共聚焦显微镜显示,vimentin(一种NK细胞中非内源性表达的蛋白)通过NKp46依赖性胞吐作用在NK细胞中显著富集。胞吐摄取的vimentin尾部结构域与CDC42竞争结合ARHGEF7,并抑制其交换活性。这种干扰损害了CDC42介导的肌动蛋白聚合,从而抑制NK细胞细胞毒性。通过将vimentin递送至NK细胞,CTC能够抑制并逃逸NK细胞的攻击。至关重要的是,药物抑制vimentin胞吐作用提高了NK细胞在体内清除CTC的功效,也提高了基于NK细胞的过继性免疫疗法的疗效。在临床上,vimentin (+) NK细胞的频率与癌症患者的CTC负荷和肿瘤复发相关。
我们的研究揭示了胞吐作用作为肿瘤诱导NK细胞耗竭的通道,并提出靶向Vimentin转移作为对抗肿瘤复发的治疗策略。
Natural killer (NK) cells frequently exhibit an exhausted state, which facilitates immune escape of circulating tumor cells (CTCs).
However, the underlying mechanisms of NK cell dysfunction remain elusive. In this study, we identified a novel immune evasion mechanism whereby tumor cells deliver Vimentin to NK cells via NKp46-dependent trogocytosis, thereby impairing NK cell cytotoxicity.
We observed the expression of nonendogenous proteins in NK cells isolated from CTCs from oral cancer patients but not in those from nondetectable patients. High-throughput proteomic analysis, flow cytometry, and confocal microscopy revealed that vimentin, a protein that is not endogenously expressed in NK cells, was significantly enriched in NK cells via NKp46-dependent trogocytosis. The tail domain of trogocytosed vimentin competed with CDC42 for binding to ARHGEF7 and inhibited its exchange activity.
This disruption impaired CDC42-mediated actin polymerization, thus suppressing NK cell cytotoxicity. By delivering vimentin to NK cells, CTCs can suppress and evade attacks from NK cells. Crucially, pharmacological inhibition of vimentin trogocytosis increased the efficacy of NK cells in clearing CTCs in vivo and that of NK cell-based adoptive immunotherapies. Clinically, the frequency of vimentin (+) NK cells is correlated with the CTC burden and tumor recurrence in cancer patients.
Our study reveals that trogocytosis acts as a conduit for the tumor-induced exhaustion of NK cells and proposes targeting Vimentin transfer as a therapeutic strategy to counteract tumor recurrence.
MEMBER ACCOUNT
登录成功会直接打开下一页。